STAT+

Doug, a retired minister, experienced reduced boredom through conversations with Jane, an AI chatbot, which provided meaningful engagement for him and eased the burden on his wife Gabriella. The article explores the role of AI in dementia care, highlighting how the chatbot offered a solution to Doug's persistent boredom.

Roche's drug establishes a new standard for treating KRAS-driven lung cancer. The article is part of a biotech newsletter discussing recent developments in the sector, including FDA regulatory updates and political changes affecting biopharma policy.

Biotech stocks have surged in 2023, with the XBI index rising 30% year-to-date and hitting a five-year high. June saw a 19% gain for the XBI, bringing it close to its 2021 peak of $175.

Tala Fakhouri, who previously worked at the FDA on AI policy, now at Parexel, criticizes the biopharma industry for misinterpreting the FDA's flexible guidance in conservative ways to avoid risk. The article highlights concerns about how industry implementation diverges from the FDA's intended approach.

The article discusses the STAT+ AI Prognosis newsletter's focus on artificial intelligence in healthcare, highlighting Multiplet, a chemistry-themed puzzle game praised for its innovative design compared to Wordle or Connections. The newsletter will pause next week but resume on July 15.

Patrick Soon-Shiong's claims about transforming pancreatic cancer treatment with novel immunotherapies are criticized for lacking clinical evidence, with a gap between his promises and actual FDA-approved outcomes. The article highlights his history in treating pancreatic cancer and the 'Bioshield' mission, while noting financial self-interest and regulatory scrutiny.

The article discusses congenital syphilis in newborns, a preventable condition with penicillin from Pfizer, and questions Abridge’s 'patient centered' claim. The author expresses frustration over preventable medical issues and emotional reactions to community stories.

Robert F. Kennedy Jr., in his role overseeing U.S. health agencies, has had mixed results in implementing his pledge to 'Make America Healthy Again' since taking the position over a year ago. He recently defended his accomplishments in a post on X, though the article notes the outcomes remain uneven.

Sanofi halted a Phase 3 study of its drug riliprubart due to lack of efficacy, while Parabilis Medicines raised $670 million in a record biotech IPO. European countries face conflicts over drug-pricing policies amid budget strains and U.S. pressure.

GSK agreed to acquire Nuvalent, a cancer-focused biotech company, for $10.6 billion in a cash deal. The transaction includes a 26% premium over Nuvalent’s 30-day average share price, with GSK paying $124 per share and spending approximately $9.4 billion in cash.

The American Diabetes Association annual conference highlights new diabetes treatments, including triple hormone receptors and a monthly obesity drug. The article summarizes key developments from the event.

Revolution Medicines' pancreatic cancer drug daraxonrasib is poised for FDA approval after showing promise in metastatic cases post-chemotherapy. The drug's potential expansion to newly diagnosed metastatic patients is under discussion following its positive reception at the ASCO plenary session.

The article discusses the implications of Pope's encyclical on AI for Catholic hospitals and healthcare, alongside comedian Ronny Chieng's humorous critique of AI replacing human creativity at a Harvard graduation. It highlights concerns about AI offloading tasks like writing and creation, while emphasizing the value of the learning process.

The ASCO meeting highlighted discussions on barriers to cancer care and new treatments, including Brian Wolpin's presentation on the daraxonrasib pancreatic cancer study, which received a sustained standing ovation. The article concludes with a farewell from Chicago and an invitation to a virtual recap.

A new phase 3 clinical trial called PROTEUS found that combining two hormone therapies before and after surgery improved outcomes for high-risk, early-stage prostate cancer patients compared to one hormone therapy. Some oncologists view this as a potential new standard of care, though interpretations of the results vary.

Scientists report early progress in engineered heart patches and GSK announces a functional cure for hepatitis B. The article also highlights potential drug launches tied to President Trump's 'most-favored nation' claims and previews the upcoming ASCO meeting in Chicago.

A small study reports that heart patches engineered from induced pluripotent stem cells (BioVAT) improved heart wall thickness and pumping ability in patients with weakened hearts. The patches aim to serve as a bridge to heart transplant or LVAD implantation, with a larger trial needed to assess durability and candidacy.

Tippi MacKenzie's team has submitted an application to the FDA for a trial to treat a rare genetic disease in fetuses using gene replacement therapy. The trial aims to treat five fetal patients with a lysosomal storage disorder. If approved, this would be a significant step towards treating genetic diseases before birth.

Senate Democrats propose adding long-term care benefit to Medicare, which would be the first new benefit in over 20 years. The plan aims to create a home care benefit and improve long-term care in Medicaid. It also includes workforce components for training and better pay for employees.

The No Surprises Act's arbitration process is resulting in out-of-network providers receiving significantly higher prices for spine surgery, with median prices reaching $34,000, compared to the usual $1,400. This has been a major benefit for providers, who are prevailing in over 80% of disputes. The law has protected patients from unexpected bills but has also led to high awards for providers.

A study found that most Canadian medical societies lack comprehensive conflict-of-interest policies, with 51.5% not having policies addressing key activities. This absence of policies has implications for doctors, patients, and the societies themselves. The lack of governance may introduce commercial bias into clinical decision-making.

The American biotech industry is divided over partnering with Chinese firms, despite spending $60 billion on Chinese molecules in the first three months of 2026. This investment is expected to double last year's total and has sparked hope for patients awaiting new medicines. However, it has also created tension among industry executives and investors.

Jillian, a 38-year-old woman, struggled with alcohol addiction and tried various treatments, including Alcoholics Anonymous meetings and therapy, but found them ineffective. She sought help to regain control over her drinking, which had already cost her a marriage and threatened her career. Jillian's experiences highlight the need for alternative and more effective treatments for alcohol addiction.

Adam, a 13-month-old boy born with a life-threatening rare disease, underwent a gene therapy treatment after a stem cell transplant failed, and later developed a golf-ball sized tumor on his brain. The tumor was revealed during a routine scan last year. Adam's parents, Mary Beth and Dave Brennan, had chosen the gene therapy option due to the high risk of death associated with a second transplant.

A new study finds that a medicine used to mitigate gene therapy side effects may also reduce its effectiveness. The trial tested a gene therapy for Dravet syndrome and used steroids and sirolimus to suppress immune responses. The results raise concerns about the balance between safety and efficacy in gene therapy.

A new liver disease called Metabolic dysfunction and alcohol-associated liver disease (MetALD) is emerging in the US, caused by a combination of heavy drinking and obesity. The condition is becoming a leading concern among doctors, with young people and women being increasingly affected. Nearly 1 in 10 US adults report overlapping heavy drinking and obesity.

Alcohol consumption is a crucial topic to discuss during doctor's visits, but it often gets skipped or compressed due to time constraints. Excessive alcohol use can cause or worsen dozens of diseases and shorten lifespans. Even moderate use has been linked to increased risk of various conditions.

Medicare spending on new Alzheimer's drugs, Leqembi and Kisunla, is lower than expected due to challenges in administration, limited patient population, and severe side effects. Medicare does not forecast significant spending on these drugs in 2026 or 2027. The drugs have had little meaningful benefits despite their approval.

The FDA is set to reconsider a treatment for rare cancer after a surprise rejection. The Trump administration claims massive savings from secret drug pricing deals. FDA leadership faces accusations of political interference in drug reviews.

Clene is developing a treatment for ALS called CNM-Au8, which is a suspension of gold nanocrystals in water. The treatment is described as a highly concentrated aqueous suspension. The author is skeptical about the treatment's effectiveness.

Sebastiaan van Heesch used a new method to analyze ribosomes in donated hearts and discovered hundreds of previously unknown mini-proteins. These 'dark proteins' may influence energy production in heart muscles. The findings could change our understanding of human disease.

The pharmaceutical industry's reputation among patient groups rose last year, with 57% of over 2,400 groups reporting a positive reputation. However, concerns remain about access and pricing. The industry's reputation is still below its 2022 level.